Publication:
Differences in hepatitis a seroprevalence among geographical regions in Turkey: : A need for regional vaccination recommendations

dc.contributor.authorCeyhan, M.
dc.contributor.authorYildirim, I.
dc.contributor.authorKurt, N.
dc.contributor.authorUysal, G.
dc.contributor.authorDıkıcı, B.
dc.contributor.authorEcevit, C.
dc.contributor.authorAydoğan, A.
dc.contributor.authorKoç, A.
dc.contributor.authorYasa, O.
dc.contributor.authorKöseoğlu, M.
dc.contributor.authorOnal, K.
dc.contributor.authorHacımustafaoğlu, M.
dc.contributor.authorÇelebi, Solmaz
dc.contributor.buuauthorHACIMUSTAFAOĞLU, MUSTAFA KEMAL
dc.contributor.buuauthorÇELEBİ, SOLMAZ
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentEnfeksiyon Hastalıkları Ana Bilim Dalı
dc.contributor.researcheridHVS-8235-2023
dc.contributor.researcheridENK-4130-2022
dc.date.accessioned2024-11-26T07:32:18Z
dc.date.available2024-11-26T07:32:18Z
dc.date.issued2008-10-01
dc.description.abstractHepatitis A is a worldwide vaccine-preventable infection. Recommendation of vaccination depends on the endemicity of the disease. The World Health Organization recommends universal hepatitis A vaccination in intermediate areas; however, there is no need of mass vaccination in high and low endemicity regions. Therefore, most of the countries are using a vaccination policy according to the endemicity characteristic representing the whole of the country. The endemicity of this infection varies due to sanitary and hygiene conditions and socioeconomic differences among the countries and in various regions of the same country. A sample of 1173 persons between the age of 0 and 91 years from nine randomly selected medical centres from five different geographical centres of Turkey were tested for the level of anti-hepatitis A virus (anti-HAV) immunoglobulin-G antibodies using an enzyme-linked immunosorbent assay. The overall prevalence of anti-HAV antibodies was 64.4% (1142/1173). While the rate of sero-positivity was over 80% in the 5-9 age group and more than 90% after 14 years of age in south-eastern and eastern regions, it was lower than 50% at the age of 5-9 years in central and western regions and remains under 80% in those areas. We conclude that the differences observed in HAV sero-positivity among various geographical regions in Turkey support a universal HAV immunization policy for children currently living in regions of intermediate endemicity.
dc.description.sponsorshipClement Weinberger of Sanofi Pasteur
dc.identifier.eissn1365-2893
dc.identifier.endpage72
dc.identifier.issn1352-0504
dc.identifier.startpage69
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2008.01034.x
dc.identifier.urihttps://hdl.handle.net/11452/48494
dc.identifier.volume15
dc.identifier.wos000258784400013
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley
dc.relation.journalJournal of Viral Hepatitis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectShifting epidemiology
dc.subjectPrevalence
dc.subjectPopulation
dc.subjectOutbreak
dc.subjectPatterns
dc.subjectChildren
dc.subjectSpain
dc.subjectArea
dc.subjectEndemicity
dc.subjectGeographical variation
dc.subjectHepatitis a virus
dc.subjectSeroprevalence
dc.subjectVaccination
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectGastroenterology & hepatology
dc.subjectInfectious diseases
dc.subjectVirology
dc.titleDifferences in hepatitis a seroprevalence among geographical regions in Turkey: : A need for regional vaccination recommendations
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Enfeksiyon Hastalıkları Ana Bilim Dalı
local.indexed.atWOS
relation.isAuthorOfPublication0f1ad7e3-4cce-40b2-bbb3-7200fae5f769
relation.isAuthorOfPublication28076e30-7802-4de2-ae05-028643d56968
relation.isAuthorOfPublication.latestForDiscovery0f1ad7e3-4cce-40b2-bbb3-7200fae5f769

Files